Soltis Investment Advisors’s Biogen BIIB Stock Holding History

Soltis Investment Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$277K	Buy	+1,283	New	+$245K	0.02%	520

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Soltis Investment Advisors's BIIB Position: Q2 2026 in Review

Soltis Investment Advisors opened a new position in Biogen (BIIB) in Q2 2026: 1,283 shares worth $277K. The stake represents 0.02% of the portfolio and ranks #520 among its holdings.

1,038 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Soltis Investment Advisors held 1,283 shares of Biogen worth $277K as of Q2 2026.
Biogen was a new Soltis Investment Advisors position in Q2 2026.
Biogen made up 0.02% of Soltis Investment Advisors's portfolio in Q2 2026, its #520 holding.
1,038 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Soltis Investment Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.